Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Once-Weekly RO7795068 in Obesity or Overweight with Type 2 Diabetes
jRCT2061250090Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and type 2 diabetes mellitus (T2DM) comparing RO7795068 once-weekly with Placebo once-weekly (2 arms). Primary endpoint: Percent change from baseline in body weight at Week 72. Started May 2026; status: recruiting.
02
Drugs
zilebesiran
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2061250090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250090.